0:00
The title of my talk is going to
be drug-eluting implants.
My name is Aliasger K. Salem.
I'm the Bighley Chair
and Professor of
Pharmaceutical Sciences at
the University of Iowa
College of Pharmacy.
0:15
With this presentation,
I'm going to talk about
drug-eluting implants and
how they can provide
sustained drug delivery.
In the field of drug delivery,
the most commonly used
treatments have traditionally
traditionally been
systemic delivered drugs
using oral or intravenous
administration.
The problems associated
with this type of
delivery is that the
drug concentration is
controlled by
first-class metabolism.
Therefore, may not always remain
within the therapeutic window.
Implantable drug
delivery systems,
which during this talk we
will also refer to as IDDs,
are an excellent alternative
to traditional delivery
because they offer
the ability to
precisely control
the drug release,
deliver drugs locally
to the target tissue,
and avoid the toxic side
effects often experienced
with systemic administration.
Since the creation
of the first FDA
approved IDDS in 1990,
there has been a surge
in research devoted to
fabricating and testing
novel IDDS formulations.
The versatility of these
systems is evident
when looking at the various
biomedical applications
that utilize IDDSs.
In this presentation,
I'm going to give
some detailed examples of
IDDs and how they work,
and I'm going to talk
about their advantages,
their disadvantages and
then give an overview
of future prospects.
When it comes to long-acting
drug delivery formulations,
the advantages of
long-acting formulations
over conventional
dosage forms include
the ability to avoid sharp
fluctuations in drug concentration,
avoid sub-therapeutic/toxic
doses
and improve patient compliance
and adherence to treatment.
If you look at this
graph for an example,
you can see that
when you're giving
single dose, immediate
release formulations,
you have periods
where you're above
that minimum safe concentration,
periods where you're below
the minimum effective
concentration
and periods of time
where you're within
that ideal region.
If you have a sustained
release formulation
or a zero-order controlled
release formulation,
you can stay within that
range that is always below
the minimum safe concentration
and above the minimum
effective concentration,
which is an ideal profile
for a sustained
release formulation.
The types of drug-eluting
implants that are available
